---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-005048"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T00:43:01.972887+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M

## Summary
- Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.
- Full-year 2023 revenue $482.4M (+20% YoY); net income $106.1M ($0.94 diluted EPS).
- Cash and investments $425.4M; 2024 revenue guidance reiterated at $600-$630M.
- NDA for relacorilant in Cushing's expected Q2 2024; GRACE results Q2; CATALYST shows 24% hypercortisolism prevalence in first 700 patients.
- ROSELLA ovarian cancer trial and DAZALS ALS trial results expected by year-end 2024.

## SEC filing metadata
- accession: 0001628280-24-005048
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/cort-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-005048
- JSON: https://secwatch.observer/filing/0001628280-24-005048.json
- Plain text: https://secwatch.observer/filing/0001628280-24-005048.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2023 results: revenue $135.4 million, net income $31.4 million, EPS $0.28. Guidance reaffirmed.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $135.4 million
  - Net income: $31.4 million
  - EPS: $0.28
  - Guidance: reaffirmed
  - Result: reported results
  source text: today reported its results for the quarter and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the year ended December 31, 2023 results: revenue $482.4 million, net income $106.1 million, EPS $0.94. Guidance reaffirmed.
  - Period: the year ended December 31, 2023
  - Revenue: $482.4 million
  - Net income: $106.1 million
  - EPS: $0.94
  - Guidance: reaffirmed
  - Result: reported results
  source text: and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • Reiterated 2024 revenue guidance of $600 – $630 million • Fourth quarter net income of $31.4 million, compared to $16.6 million in fourth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.